Defense Tech Stocks and IPO’s Surge with Defense Spending

 

Defense Tech Stocks and IPO’s Surge with Defense Spending

 

Stocks Mentioned: (Nasdaq: $VWAV), @VWAVInc (NASDAQ: $VOYG), (NASDAQ: $AIRO), (NYSE: $KRMN), (NASDAQ: $PLTR)

 

 

 

Investorideas.com, a leading investment platform for trading and investment ideas in space and defense stocks, releases a sector snapshot highlighting recent IPOs and new listings in the defense tech industry, featuring recently NASDAQ listed, VisionWave Holdings, Inc. (Nasdaq: VWAV).

 

With significant US defense spending commitments, emerging defense companies are gaining momentum. The US defense budget for 2025 is estimated at $962 billion, making it the world's largest military budget. In 2025, the defense industry is experiencing a major transformation due to geopolitical pressures, technological breakthroughs, and shifting capital flows; and the market is paying attention. 

 

Paid News Dissemination on behalf of VWAV

 

Read this article, featuring VWAV in full at https://www.investorideas.com/news/2025/defense/07231Defense-Tech-Stocks-and-IPOs-Surge-with-Defense-Spending.asp

Looking at what is happening in the sector Morningstar reported, “Voyager Technologies  (NASDAQ: VOYG) closed its first day of trading on the New York Stock Exchange at $56.48 per share, giving it an 82% pop from its IPO price. It’s a temperature check for the hottest sector in venture capital outside of artificial intelligence: defense tech.”

 

Aiming to capitalize on this opportunity, VisionWave Holdings, Inc. (Nasdaq: VWAV), a next-generation defense technology company seeking to redefine battlefield superiority through AI-powered autonomy and advanced multi-domain sensing, today announced that its common stock and warrants began trading on the Nasdaq Global Market under the symbols “VWAV” and “VWAVW” on July 15, 2025, following the successful completion of its business combination.

 

From the news: VisionWave enters the public markets at a moment of increased demand for intelligent defense solutions. According to Technavio, a leading global technology research and advisory company, global defense-related IT spending is set to grow by over $23 billion from 2024 to 2028 consistent with overall defense expenditure expected to surpass  $2.3 trillion by 2028. 

 

Moreover, the U.S. government’s 2025 “Big Beautiful Bill” earmarks approximately $16 billion for military AI, along with at least $1.4 billion in targeted DoD/NNNSA AI and autonomy investments. VisionWave believes it is strategically positioned during this period of expected market transformation.

 

“VisionWave was founded to lead the next evolution of defense autonomy, scaling technologies that respond in real time and adapt in the field with the goal of outperforming legacy systems—saving lives and changing how wars are won,” said Noam Kenig, CEO of VisionWave.

 

At the heart of VisionWave’s offering is a real-time, adaptive AI core that powers high-resolution radar, low-SWaP RF imaging, and multispectral sensing. These proprietary systems enable autonomous operation across air, land, and sea that are designed to deliver actionable intelligence and mission-critical awareness in seconds, not minutes.

 

The platform is designed to replace legacy systems that are slow, siloed, and outdated, giving war fighters, border patrol, and homeland security forces a decisive edge in modern threat environments.

 

VisionWave is already engaged with Tier-1 defense manufacturers and national security programs across the U.S. and allied nations, with several pilots and technical evaluations underway.

 

Near-term priorities include:

·        Accelerating commercialization of Vision-RF, super-resolution radar, and AI sensing systems

·        Investing in the Company’s proprietary AI core, the foundation of all products

·        Establishing U.S. manufacturing operations and expanding R&D capabilities in Canada

·        Fast-tracking co-development partnerships with leading defense integrators

·        Pursuing active defense contracts with U.S. agencies and Golden Dome initiatives

 

These strategic moves are designed to rapidly scale operations, solidify VisionWave’s competitive edge, and generate long-term value for shareholders.

 

Douglas Davis, Executive Chairman of VisionWave, added:

“The Nasdaq listing is not just a milestone—it is a launchpad. We have built the tech, the team, and the partnerships. Now we are scaling to meet global demand for intelligent, mission-adaptive defense systems.”

 

Business Combination Highlights:

·        Post-merger enterprise value of approximately $174 million

·        Approximately 14.3 million shares of common stock outstanding

·        No PIPE or minimum cash condition at closing

·        Bannix Acquisition Corp. and VisionWave Technologies now wholly owned by VisionWave Holdings, Inc.

 

On June 16, 2025 AIRO Group Holdings, Inc. (NASDAQ: AIRO), a company specializing in advanced aerospace and defense technologies, announced the closing of its initial public offering of 6,900,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase 900,000 additional shares, at a public offering price of $10.00 per share.  

 

The stock traded as high as over $39 following its IPO and is currently trading in the $22- 23.00 range.

 

AIRO is organized into four operating segments, each of which represents a critical growth sector in the aerospace and defense market: Drones, Avionics, Training, and Electric Air Mobility.

 

AIRO recently announced plans to expand its US footprint with the addition of a new manufacturing and engineering development facility. This strategic move builds on the success of AIRO’s existing operations and is driven by the growing global demand for AIRO’s flagship product, the RQ-35 ISR Drone.

 

The RQ-35 ISR Drone has rapidly gained international recognition for its reliability, performance, and mission versatility across defense and security sectors. Known in military applications as the RQ-35 Heidrun, the system offers significant advantages over existing micro-ISR drones due to its combination of full autonomy, long flight endurance, and ease of operation. It has been rigorously tested and deployed in harsh electronic warfare and GPS-denied environments, including active conflict zones, where it has demonstrated exceptional resilience and effectiveness.

 

In February, Karman Holdings Inc. (NYSE: KRMN), a leader in the rapid design, development and production of critical next-generation system solutions for launch vehicle, satellite, spacecraft, missile defense, hypersonic and UAS customers, announced the pricing of its initial public offering of 23,000,000 shares of its common stock at a public offering price of $22.00 per share.

 

With the stock closing at over $56.00 on July 21st, the company announced preliminary second quarter fiscal year 2025 financial results in connection with an underwritten public offering (the "Offering") of 20,000,000 shares of its common stock being offered by certain selling stockholders. The selling stockholders expect to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock. The Company is not selling any shares of common stock and will not receive any proceeds from the sales of shares in the Offering. The Company also announced it will issue financial results for the Company’s second quarter fiscal year 2025 after financial markets close on Thursday, August 7, 2025.

 

From the news: For the three months ended June 30, 2025, we expect net income to be between $6.17 million and $6.20 million, compared to net income of $4.60 million for the three months ended June 30, 2024.

 

For the three months ended June 30, 2025, net income margin is expected to be 5.4%, compared to net income margin of 5.4% for the three months ended June 30, 2024.

For the three months ended June 30, 2025, we expect funded backlog to be between $712.00 million and $715.00 million, representing an estimated increase of approximately 34.8% and 35.4%, compared to funded backlog of $528.01 million for the three months ended June 30, 2024.

 

Defense tech, and specifically AI-driven defense technology, is making headlines based on money flow. On July 4, 2025, President Donald Trump enacted the ‘One Big Beautiful Bill Act’, allocating billions of dollars to US technology, defense, infrastructure and border security.

 

Companies like AI /Defense tech company Palantir Technologies Inc. (NASDAQ: PLTR) paved the way for investors in 2025 with its performance, and new defense stocks are now benefiting from the momentum.

 

Get more defense aerospace stock investing ideas with Investorideas.com free stock directory

 

 

 

 

Sign up for free trading and stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Disclaimer/Disclosure:  VisionWave Holdings, Inc. is a paid monthly featured defense stock on  Investorideas.com. Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions. More disclosure info can be found here. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800 665 0411

Defense AI Stock VisionWave Holdings, Inc. (NASDAQ: $VWAV) Joins Nasdaq with Goal to Redefine Battlefield Superiority; @VWAVInc

 

 

Defense AI Stock VisionWave Holdings, Inc. (NASDAQ: $VWAV) Joins Nasdaq with Goal to Redefine Battlefield Superiority; @VWAVInc

 

 

WEST HOLLYWOOD, CA – July 22, 2025 — ( Investorideas.com Newswire) – Breaking defense stock news- VisionWave Holdings, Inc. (“VisionWave” or the “Company”) (Nasdaq: VWAV), a next-generation defense technology company seeking to redefine battlefield superiority through AI-powered autonomy and advanced multi-domain sensing, today announced that its common stock and warrants began trading on the Nasdaq Global Market under the symbols “VWAV” and “VWAVW” on July 15, 2025, following the successful completion of its business combination.

 

Positioned for Market Disruption

VisionWave enters the public markets at a moment of increased demand for intelligent defense solutions. According to Technavio, a leading global technology research and advisory company, global defense-related IT spending is set to grow by over $23 billion from 2024 to 2028 consistent with overall defense expenditure expected to surpass  $2.3 trillion by 2028. 

 

Moreover, the U.S. government’s 2025 “Big Beautiful Bill” earmarks approximately $16 billion for military AI, along with at least $1.4 billion in targeted DoD/NNNSA AI and autonomy investments. VisionWave believes it is strategically positioned during this period of expected market transformation.

Paid News Dissemination on behalf of VWAV

Read this news, featuring VWAV in full at: https://www.investorideas.com/news/2025/defense/07221VWAV-VisionWave-Holdings-Inc-Accelerate-AI-Driven-Defense-Technology.asp

 

“VisionWave was founded to lead the next evolution of defense autonomy, scaling technologies that respond in real time and adapt in the field with the goal of outperforming legacy systems—saving lives and changing how wars are won” said Noam Kenig, CEO of VisionWave.

 

VisionWave’s Battlefield-Ready Platform

At the heart of VisionWave’s offering is a real-time, adaptive AI core that powers high-resolution radar, low-SWaP RF imaging, and multispectral sensing. These proprietary systems enable autonomous operation across air, land, and sea that are designed to deliver actionable intelligence and mission-critical awareness in seconds, not minutes.

 

The platform is designed to replace legacy systems that are slow, siloed, and outdated, giving war fighters, border patrol, and homeland security forces a decisive edge in modern threat environments.

 

Strategic Focus and Expansion

VisionWave is already engaged with Tier-1 defense manufacturers and national security programs across the U.S. and allied nations, with several pilots and technical evaluations underway.

 

Near-term priorities include:

·        Accelerating commercialization of Vision-RF, super-resolution radar, and AI sensing systems

·        Investing in the Company’s proprietary AI core, the foundation of all products

·        Establishing U.S. manufacturing operations and expanding R&D capabilities in Canada

·        Fast-tracking co-development partnerships with leading defense integrators

·        Pursuing active defense contracts with U.S. agencies and Golden Dome initiatives

 

These strategic moves are designed to rapidly scale operations, solidify VisionWave’s competitive edge, and generate long-term value for shareholders.

 

Douglas Davis, Executive Chairman of VisionWave, added:

“The Nasdaq listing is not just a milestone—it is a launchpad. We have built the tech, the team, and the partnerships. Now we are scaling to meet global demand for intelligent, mission-adaptive defense systems.”

 

Business Combination Highlights:

·        Post-merger enterprise value of approximately $174 million

·        Approximately 14.3 million shares of common stock outstanding

·        No PIPE or minimum cash condition at closing

·        Bannix Acquisition Corp. and VisionWave Technologies now wholly owned by VisionWave Holdings, Inc.

 

About VisionWave Holdings Inc.

 

VisionWave Holdings, Inc. is at the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. Its state-of-the-art innovations— ranging from high-resolution radars and advanced vision systems to radio frequency (RF) sensing technologies are seeking to redefine operational efficiency and precision for military and homeland security applications worldwide. From tactical ground vehicles to precision weapon control systems, VisionWave leads the development of reliable, high-performance technologies that transform defense strategies and deliver superior results, even in the most challenging environments. With headquarters in the U.S. and strategic partnerships in Canada and the United Arab Emigrants, VisionWave is uniquely positioned to serve global markets, offering cutting-edge defense solutions that address the evolving needs of security forces across the world.

 

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the estimated implied enterprise value of the Combined Company, VisionWave Holdings’ ability to scale and grow its business, the advantages and expected growth of the Combined Company, the Combined Company’s ability to source and retain talent, and the cash position of the Combined Company following closing of the Business Combination, as applicable. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of VisionWave Technologies’ management and are not predictions of actual performance.

 

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although each of BNIX, VisionWave Technologies and VisionWave Holdings believes that it has a reasonable basis for each forward-looking statement contained in this press release, each of BNIX, VisionWave Technologies and VisionWave Holdings cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the definitive proxy statement/prospectus mailed to BNIX stockholders, and filed by the Combined Company with the SEC and other documents filed by the Combined Company or BNIX from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. BNIX, VisionWave Technologies and VisionWave Holdings cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the ability to recognize the anticipated benefits of the Business Combination, costs related to the Business Combination, the risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business Combination, the outcome of any potential litigation, government or regulatory proceedings, and other risks and uncertainties, including those to be included under the heading “Risk Factors” in the definitive proxy statement/prospectus mailed to BNIX stockholders, and those included under the heading “Risk Factors” in the annual report on Form 10-K for the fiscal year ended December 31, 2024, of BNIX and in its subsequent quarterly reports on Form 10-Q and other filings with the SEC. There may be additional risks that BNIX, VisionWave Technologies and VisionWave Holdings presently do not know or that the parties currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of BNIX, VisionWave Technologies and VisionWave Holdings as of the date of this press release. Subsequent events and developments may cause those views to change. However, while BNIX, VisionWave Technologies and VisionWave Holdings may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of BNIX, VisionWave Technologies and VisionWave Holdings as of any date subsequent to the date of this press release. Except as may be required by law, BNIX, VisionWave Technologies and VisionWave Holdings do not undertake any duty to update these forward-looking statements.

 

More information about VisionWave can be found at https://vwav.inc

 

You can also follow us on social media at:

https://x.com/VWAVInc

 

Contact:

VisionWave Holdings Investor Relations

Douglas Davis, Executive Chairman of the Board

(302) 305-4790

 

Learn more about VisionWave Holdings Inc (NASDAQ: VWAV)

https://www.investorideas.com/CO/BNIX/

 

Get more defense aerospace stock investing ideas with Investorideas.com free stock directory

 

 

 

 

Sign up for free trading and stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Disclaimer/Disclosure: VisionWave Holdings Inc is a paid for featured defense company on Investorideas.com .Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.

More disclosure info can be found here. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

 

Follow us on Facebook https://www.facebook.com/Investorideas

 

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

 

800 665 0411

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) Reports Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort

 

 

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) Reports Positive Data Safety Monitoring Board Review and Recommendation to  Advance to Next Clinical Trial Cohort

 

 

SAN DIEGO, CA, July 15, 2025 – (Investorideas.com Newswire)  Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device  for Oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing  its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review and recommended advancing to the next patient cohort without modification.

 

The trial, titled “Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors Who Have Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab”, is being conducted to assess the Hemopurifier’s safety, feasibility, and optimal dosing.

 

The DSMB- comprising independent medical experts in nephrology and oncology- reviewed data from the initial cohort of three participants, each of whom received a single 4-hour Hemopurifier treatment.  Based on their evaluation, the board found no safety concerns and confirmed that the Hemopurifier continues to demonstrate a favorable safety and tolerability profile. To date, no serious adverse events (SAEs) or Dose-Limiting Toxicities (DLTs) related to the Hemopurifier have been reported.

 

Paid News Dissemination of behalf of AEMD.

 

Read this news, featuring AEMD in full at https://www.investorideas.com/news/2025/07151AEMD-Positive-Data-Safety-Monitoring-Board-Review.asp

 

 

"The DSMB's positive recommendation is encouraging and underscores the favorable safety profile observed to date in patients with cancer," according to Steven LaRosa, M.D, Chief Medical Officer of Aethlon Medical. "This marks a significant step forward in the clinical development program for the Hemopurifier in Oncology and brings the company closer to potentially addressing the significant unmet medical need for the approximately 60-70% of patients with cancer who do not experience a lasting clinical response to anti-PD-1 immunotherapy.”

 

Enrollment for Cohort 2 is now open. In this phase, participants will receive two Hemopurifier treatments over a one-week period at the study’s three active clinical sites in Australia. This trial, which aims to enroll approximately 9 to 18-patients, is designed to evaluate the safety, feasibility of administering the Hemopurifier at varying dosing intervals in patients with solid tumors who have stable or progressive disease, while receiving treatment that includes Pembrolizumab (Keytruda®) or Nivolumab (Opdivo®). 

 

The primary endpoint of this trial is the incidence of adverse events and clinically significant changes in safety laboratory tests of Hemopurifier- treated patients. In addition to safety monitoring, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body’s own natural ability to attack tumor cells. These findings are expected to inform the design of a future efficacy and safety, Premarket Approval (PMA), study required by regulatory authorities.

 

Aethlon Medical, Inc. remains committed to advancing the Hemopurifier for use in oncology and will continue to provide updates as the clinical trial progresses.

 

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.

 

The Hemopurifier holds a U.S. Food and Drug Breakthrough Device for:

·        The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and

·        The treatment of life-threatening viruses not addressed with approved therapies.

 

The Hemopurifier is being developed under an open Investigational Device Exemption (IDE) for both indications.

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids. For more information visit www.AethlonMedical.com and follow the company on LinkedIn.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such include, without limitation, the number of patients who receive pembrolizumab or nivolumab that will have lasting clinical responses to these agents; device deficiencies or immediate complications; the possibility of novel treatment strategies; how the Hemopurifier may reduce tumor-derived extracellular vesicles and enhance T cell activity against tumors; the efficacy of continued clinical trials; development under IDE for indications; and/or the number of patients enrolled in each cohort. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Aethlon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

 

Get more biotech and medical tech news, articles, podcasts and stock directories

 

 

 

About Investorideas.com https://www.investorideas.com/About/